{"filings":[{"id":91575,"accession_number":"0001683168-26-002613","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"PharmaCyte shareholders approve reverse stock split and increase equity plan shares by 2M at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved reverse stock split at ratio 1:1.1 to 1:100; 5,067,304 for, 2,280,497 against.","Approved amendment to 2022 Equity Incentive Plan increasing share reserve by 2,000,000 shares.","Elected five directors (Silverman, Schechter, Abecassis, Weinstein, Walker) to hold office until 2027 annual meeting.","Ratified CBIZ CPAs P.C. as independent auditor for FY ending April 30, 2026; 6,837,442 for votes.","Non-binding advisory approval of executive compensation received majority support (3,306,883 for votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118090,"accession_number":"0001683168-25-008947","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"PharmaCyte Biotech receives Nasdaq notice of non-compliance with $1.00 minimum bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received Dec 1, 2025; stock closed below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until June 1, 2026, to regain compliance.","To regain compliance, closing bid price must be at least $1.00 for 10 consecutive business days.","If not cured by June 1, 2026, Company may seek a second 180-day period or face delisting.","Options under consideration include a reverse stock split, subject to stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118088,"accession_number":"0001683168-25-008512","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K/A","filed_at":"2025-11-18T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"PharmaCyte acquires $3M convertible stake in Q/C Technologies; Q/C has going concern","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["PharmaCyte bought Q/C Series H convertible preferred shares and warrants for $3M, convertible into 600,000 common shares each.","Q/C's auditors express substantial doubt about its ability to continue as a going concern due to net losses and negative cash flows.","Pro forma combined financials reflect the transaction; Q/C's financial statements show recurring operating losses.","Warrants expire five years after stockholder approval of issuance exceeding 19.99% of Q/C outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118089,"accession_number":"0001683168-25-007871","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"PharmaCyte stockholders authorize share issuance and approve 2.25M share increase to equity plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders authorized issuance of shares underlying convertible preferred stock and warrants per August 2025 SPA (1,649,395 for, 249,100 against).","Amendment to 2022 Equity Incentive Plan approved, increasing share reserve by 2,250,000 shares (2,348,827 for, 399,696 against).","All three proposals passed at special meeting on Oct 30, 2025, with ~37.1% quorum (2,866,944 shares voted).","Proposal 3 (adjournment) also passed: 2,496,898 for, 311,836 against, 58,210 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134537,"accession_number":"0001683168-25-006727","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"PharmaCyte Biotech invests $3M in TNF Pharma for convertible preferred and warrants linked to LightSolver license","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PharmaCyte purchased $3M of TNF Series H convertible preferred shares (convertible at $5) and warrants for 600,000 common shares at $5 exercise price.","Investment supports TNF's license with LightSolver for a light-speed computing platform for cryptocurrency mining and blockchain.","TNF plans to change its name and ticker to reflect the new strategy; warrants expire 5 years after stockholder approval.","Preferred shares carry 7% annual dividend (15% on trigger events) and price-based anti-dilution adjustments.","PharmaCyte reports total assets over $55M as of April 30, 2025, and will use cash for this investment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134536,"accession_number":"0001683168-25-006274","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"PharmaCyte raises $7M in private placement of Series C convertible preferred and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sale of 7,000 shares of Series C preferred (stated value $1,000) convertible into 7M common at $1.00 per share.","Warrants to purchase 7M common shares at $1.00, exercisable immediately for 5 years.","Preferred shares accrue a 7% quarterly dividend payable in cash; 15% upon trigger event.","Company must seek stockholder approval by Oct 31, 2025 to issue >19.99% of outstanding common.","Proceeds used for general corporate purposes and working capital; closing expected Aug 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151383,"accession_number":"0001683168-25-002790","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PharmaCyte Biotech annual meeting elects directors, ratifies auditor, approves exec compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting held Apr 24, 2025; quorum of 3,222,988 shares (~46.92%) present.","All five director nominees elected: Silverman, Schechter, Abecassis, Weinstein, Walker.","CBIZ CPAs P.C. ratified as auditor for FY ending Apr 30, 2025 (for: 3,123,042; against: 72,371).","Non-binding advisory vote approved executive compensation (for: 1,094,399; against: 113,815; abstain: 21,543)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170273,"accession_number":"0001683168-25-001236","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"PharmaCyte Biotech auditor Marcum resigns, replaced by CBIZ CPAs P.C.; material weaknesses reiterated","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Marcum LLP resigned as independent auditor on Feb 21, 2025, effective upon CBIZ CPAs P.C. acquiring Marcum's attest business.","Audit Committee immediately engaged CBIZ CPAs P.C. as successor independent registered public accounting firm.","No disagreements with Marcum on accounting principles or audit scope during FYE April 30, 2024 or interim period.","Material weaknesses disclosed in prior 10-K remain: insufficient segregation of CFO duties and insufficient management review controls.","Marcum provided letter to SEC agreeing with the company's statements regarding the change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220370,"accession_number":"0001683168-24-003796","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["1.01","2.01","8.01","9.01"],"status":"ready","headline":"PharmaCyte invests $7M in MyMD for convertible preferred stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Invests $7M for Series G Convertible Preferred Stock convertible into 3,854,626 MyMD common shares at $1.816 per share.","Also receives warrants to purchase up to 3,854,626 MyMD common shares (5-year and 18-month terms) at $1.816 per share.","Gets right to nominate one board member while owning >20% of MyMD common stock on as-converted basis.","MyMD filed Certificate of Designations for Series G Preferred with 10% annual dividend, compounded monthly.","MyMD is a clinical-stage biopharma with Phase 2 data in sarcopenia (MYMD-1) and advancing toward FDA discussions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220369,"accession_number":"0001683168-24-002881","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PharmaCyte Biotech shareholders elect all five directors and approve auditor ratification at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 53.41% of outstanding shares represented at the April 29, 2024 annual meeting.","All five director nominees elected: Silverman, Schechter, Abecassis, Weinstein, and Walker, each with approximately 88-93% of votes cast For.","Ratification of Marcum LLP as independent auditor approved with 4,387,273 For, 109,167 Against, 18,447 Abstain.","Non-binding advisory vote on executive compensation passed with 1,922,352 For, 186,215 Against, 50,866 Abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257534,"accession_number":"0001683168-23-008446","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2023-11-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"PharmaCyte grants $100K cash and 170K options to CEO, $50K cash and 85K options to CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One-time grant to Joshua Silverman (Interim CEO): $100,000 cash and options to purchase 170,000 shares at $2.18/share.","One-time grant to Carlos Trujillo (CFO): $50,000 cash and options to purchase 85,000 shares at $2.18/share.","Options vest 50% on grant date (Nov 20, 2023) and 50% on one-year anniversary.","Grants made under the PharmaCyte Biotech 2022 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257533,"accession_number":"0001683168-23-008204","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"PharmaCyte Biotech invests $5M in Femasys, expanding strategy to utilize $74.6M cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PharmaCyte (PMCB) purchases $5M senior unsecured convertible notes from Femasys (FEMY) at 6% interest, maturing in 2 years.","Notes convertible at $1.18/share; warrants to buy up to ~8.5M FEMY shares at $1.18 and $1.475 per share.","Interim CEO Josh Silverman will join Femasys' Board of Directors; collaboration agreement for joint research.","PharmaCyte had $74.6M cash as of July 31, 2023; investment marks first external tech deployment.","Femasys offers women's health products including late-stage FemBloc and FDA-cleared FemaSeed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257532,"accession_number":"0001683168-23-007830","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"PharmaCyte Biotech engages Marcum LLP as new independent auditor after Armanino resignation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Armanino resigned as independent auditor on August 1, 2023, citing exit from public company audit practice.","Marcum LLP was engaged as new independent registered public accounting firm on November 5, 2023.","No disagreements or reportable events occurred with Armanino during the past two fiscal years or subsequent period.","Company had not consulted Marcum on accounting principles or audit opinions prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274876,"accession_number":"0001683168-23-006331","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"PharmaCyte shareholders approve authorized share increase to 200M and financing-related issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved issuance of shares ≥20% of outstanding related to May 2023 Securities Purchase Agreement (convertible preferred & warrants).","Increase in authorized common stock from 133,333,334 to 200,000,000 approved; amendment filed Sept 6, 2023.","Quorum: 11,422,363 shares (~68.01%). Proposal 1: 7.17M for, 0.4M against; Proposal 2: 9.98M for, 1.02M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274875,"accession_number":"0001683168-23-005293","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Auditor Armanino LLP resigns due to exit from public audits; no disagreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Armanino resigned effective upon new auditor appointment or filing of Q for Jan 31, 2024.","Resignation solely due to Armanino's exit from public company audit services, not company-related.","No disagreements on accounting principles or reportable events in FY 2022 and FY 2023.","Company began process to engage a new independent auditor for FY ending April 30, 2024.","Armanino's audit reports for recent fiscal years were unqualified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274874,"accession_number":"0001683168-23-004985","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"PharmaCyte Biotech postpones special meeting to Aug 31; adopts bylaw amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bylaw amendment allows board to fix record date for adjourned meetings under Nevada law.","Special meeting postponed from July 7 to August 31, 2023 to accommodate a new shareholder proposal.","Location and record date for the special meeting remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292234,"accession_number":"0001683168-23-003169","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["1.01","3.02","5.03","5.07","8.01","9.01"],"status":"ready","headline":"PharmaCyte announces $35M convertible preferred financing and tender offer for up to 7.75M shares at $3.25","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raises ~$35M via sale of 35,000 Series B convertible preferred shares and warrants to existing investors.","Preferred stock convertible at $4.00/share; warrants exercisable at $4.00/share for up to 8.75M shares, expiring in 5 years.","Commences cash tender offer for up to 7,750,000 common shares at $3.25/share, expiring June 9, 2023.","Tender offer funded from cash on hand; CEO cites no definitive timeframe for pancreatic cancer asset.","Preferred shares carry 4% annual dividend, redeemable monthly starting Nov 9, 2023; subject to Nasdaq approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312945,"accession_number":"0001683168-23-000500","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PharmaCyte Biotech authorizes new $10M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $10M of common stock, effective immediately for two years.","Prior program (June 2022) repurchased ~3.41M shares for ~$9.3M as of filing date.","Program will be funded from available cash; CEO cites strong balance sheet and shareholder commitment.","Company continues evaluating internal programs and exploring strategic opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331469,"accession_number":"0001683168-22-008705","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-12-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PharmaCyte Biotech shareholders approve reverse stock split, increase authorized shares to 133M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio of 1:5 to 1:20 approved with 11,385,563 votes for, 2,067,045 against.","Authorized common shares increased from 33,333,334 to 133,333,334 approved with 11,020,851 for.","2022 Equity Incentive Plan approved with 6,532,612 for, 1,162,890 against.","All five director nominees elected; Armanino LLP ratified as auditor for FY ending April 30, 2023.","Advisory vote on executive compensation passed; frequency of every year selected by 7,493,683 votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331468,"accession_number":"0001683168-22-007894","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"PharmaCyte appoints Robert Weinstein to Board, removes cumulative voting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Weinstein appointed to Board on Nov 14, 2022; chairs Audit Committee and will join Nominating Committee if elected at Dec 28, 2022 annual meeting.","Interim CEO Joshua Silverman's month-to-month employment formalized; monthly salary set at $31,250.","Bylaw amended to eliminate cumulative voting for directors; elections now decided by plurality vote.","Board expanded from five to six members effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331467,"accession_number":"0001683168-22-007359","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Jack E. Stover resigns from PharmaCyte Biotech board effective Nov 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jack E. Stover resigned from the board of directors effective November 1, 2022.","Resignation was not due to any disagreement with the company.","No replacement for Mr. Stover was announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331466,"accession_number":"0001683168-22-006911","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-10-14T23:59:59+00:00","items":["5.02","5.08","8.01","9.01"],"status":"ready","headline":"PharmaCyte CSO resigns; board sets annual meeting Dec 28, continues $10M buyback","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CSO Gerald W. Crabtree resigned effective Oct 12, 2022; receives $29,694.88 in accrued wages, PTO, and 3 months base salary.","Board set 2022 Annual Meeting for Dec 28, 2022; director nominations due by Oct 28, 2022.","Board authorized continuation of up to $10M stock repurchase program; adopted 10b5-1 plan on Oct 13, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331465,"accession_number":"0001683168-22-006803","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-10-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PharmaCyte CEO resigns; interim CEO appointed; Board forms Business Review Committee to evaluate strategic options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Kenneth Waggoner resigned effective Oct 6; separation agreement provides $216,667 lump sum and $433,333 consulting payments over 12 months.","Board appointed Joshua Silverman as interim CEO and Chairman; Silverman is a director since Aug 2022 and co-founder of Parkfield Funding.","Board's Business Review Committee to evaluate opportunities including FDA clinical hold on Cell-in-a-Box IND and relationship with SG Austria.","Company continuing share repurchase program of up to $10 million; spending on programs curtailed pending review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348993,"accession_number":"0001683168-22-005782","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-08-16T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"PharmaCyte (PMCB) reaches cooperation deal with Iroquois; appoints five new independent directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Five prior directors resigned; five new directors appointed to reconstituted 7-member board effective Aug 15, 2022.","Iroquois, holding ~6.7% stake, gets two appointees (Schechter, Silverman); standstill until Sept 30, 2024 or later.","New independent directors: Allen, Farb, Stover join existing directors Waggoner and Abecassis.","New directors receive $12,500/quarter cash retainer, 334 shares, and option for 334 shares with five-year term.","Iroquois agreed to customary standstill, including voting and ownership limits (14.9% cap) through standstill period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348992,"accession_number":"0001683168-22-005186","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PharmaCyte Biotech rejects Iroquois Capital's consent solicitation to control board and cash reserves","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Iroquois Capital, a 7% holder, seeks to expand board from 7 to 15 and elect 8 nominees to gain control of $80M+ cash.","Company says Iroquois proposals are full of factual inaccuracies and would disenfranchise shareholders; urges ignoring consent cards.","PharmaCyte states Iroquois slate has limited biopharma experience; claims seven similar Iroquois board additions led to avg 30%+ stock decline.","Company reports ~90% of FDA clinical hold requests completed; two-phase pig study is last major item, progress could be jeopardized.","PharmaCyte engaged in settlement talks with Iroquois but they rejected; Iroquois bought shares at low price and sold immediately, per company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348991,"accession_number":"0001683168-22-005063","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-07-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PharmaCyte Biotech commences pilot phase of pig study to address FDA clinical hold for pancreatic cancer trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pilot study in two Yorkshire pigs evaluates microcatheter delivery of CypCaps into pancreatic arterial system.","Data will finalize full-scale 90-pig study protocol; results to be presented to FDA in Type A meeting.","Study aims to lift clinical hold on planned Phase 2b trial for locally advanced inoperable pancreatic cancer (LAPC).","CypCaps contain radiopaque microspheres to track movement via imaging and histology over one-week observation.","Study conducted by CBSET, Inc. in Lexington, MA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348990,"accession_number":"0001683168-22-005036","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-07-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PharmaCyte reports positive interim results in malignant ascites mouse model study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study conducted by Heidelberg Pharma using colon carcinoma cells from Austrianova Master Cell Bank in mice.","Initial data indicates overall tumor volume (Sugarbaker-index) more accurate than fluorescence for tumor burden.","Objectives include optimizing tumor cell dose, timing curve, and assessment method.","CEO Kenneth Waggoner says study proceeding as hoped; confident all objectives will be achieved.","Malignant ascites has no approved treatment; therapy aims to slow or eliminate fluid accumulation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348989,"accession_number":"0001683168-22-004874","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-07-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PharmaCyte Biotech reports FY2022 net loss of $4.2M; cash at $85.4M; authorizes $10M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents of $85.4M as of April 30, 2022; no debt mentioned.","Net loss of ~$4.2M ($0.27 per share) compared to net loss of $3.6M ($2.45 per share) in prior year.","Operating expenses increased to ~$4.4M from $3.6M, mainly due to Nasdaq listing and $90M capital raises.","Board authorized up to $10M share repurchase program, to begin after release of preliminary results.","CEO says company expects to begin two-phase pig study, the last major FDA requirement for phase 2b LAPC trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365814,"accession_number":"0001683168-22-004361","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-06-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PharmaCyte defends board and strategy against Iroquois Capital; accelerates pancreatic cancer trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company expects to begin Phase 2b pancreatic cancer trial immediately upon FDA lifting clinical hold, saving ~6 months.","Board plans to add capital markets experience; Iroquois has not recommended any candidate despite offer.","New executive compensation agreements tie cash and equity bonuses to achievement of corporate goals.","Company raised ~$90M in two capital raises and uplisted to Nasdaq; cash provides strategic advantage.","Company reiterates strategy will deliver higher shareholder value over time; rejects Iroquois' characterizations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365813,"accession_number":"0001683168-22-004190","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-06-07T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"PharmaCyte Biotech sets 2022 Annual Meeting for Aug 25; proposals due June 24","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2022 Annual Meeting of Stockholders scheduled for August 25, 2022.","Stockholder proposals and director nominations must be delivered by June 24, 2022.","Meeting date is more than 30 days from the 2021 annual meeting anniversary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365812,"accession_number":"0001683168-22-002580","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-04-13T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"PharmaCyte raises CEO and CFO salaries; Nasdaq confirms listing compliance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Kenneth Waggoner salary increased from $375K to $520K, retroactive to Jan 1, 2022.","CFO Carlos Trujillo salary increased from $275K to $380K, retroactive to Jan 1, 2022.","Nasdaq Staff determined company meets independent director requirement after appointing Dr. Matthias Löhr."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365811,"accession_number":"0001683168-22-002335","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-04-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PharmaCyte Biotech appoints Dr. Matthias Löhr to Board to fill vacancy from Yuen's death","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Löhr appointed to Board on March 31, 2022; vacancy created by death of Thomas C.K. Yuen.","Compensation: $12,500 cash per quarter, annual grant of 334 restricted shares and a 5-year option for 334 shares (fully vested).","Dr. Löhr is Professor of Gastroenterology & Hepatology at Karolinska Institute; led prior Phase 1/2 and Phase 2 trials of the company's pancreatic cancer treatment.","He will serve on the Compensation and Nominating Committees; independence under Nasdaq rules confirmed.","No family relationships or related party transactions with the company disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385336,"accession_number":"0001683168-22-001550","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-03-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PharmaCyte Biotech posts corporate presentation on its website; no financial or clinical updates disclosed.","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company made a corporate presentation available on its website for investor and analyst use.","Presentation contains standard forward-looking statements and disclaimers; no specific figures or milestones provided.","No material new information about pipeline, financials, or business developments was disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385335,"accession_number":"0001683168-22-001345","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"PharmaCyte Biotech receives Nasdaq board independence deficiency notice after director death","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Independent director Thomas C.K. Yuen passed away Feb 13, 2022, triggering noncompliance with Nasdaq Listing Rule 5605(b)(1).","Cure period: until earlier of next annual shareholders' meeting or Feb 13, 2023; if meeting before Aug 12, 2022, compliance by Aug 12, 2022.","Company expects to appoint a new independent director to regain compliance before the cure period expires."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385334,"accession_number":"0001683168-22-001119","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2022-02-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Pharmacyte Biotech notifies Nasdaq of board independence non-compliance after director death","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Board member Thomas C.K. Yuen died Feb 13, 2022; company notified Nasdaq Feb 15, 2022.","Due to his death, majority of board no longer independent, violating Nasdaq Listing Rule 5605(b)(1).","Company has automatic cure period; expects to regain compliance by appointing new independent director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422134,"accession_number":"0001683168-21-004199","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2021-09-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PharmaCyte posts corporate presentation on website; no material updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed under Item 7.01; presentation available on company website.","Exhibit 99.1 contains only forward-looking statements boilerplate; no new financial or operational data provided.","No earnings, guidance, or business milestones announced in the filing or exhibit.","Presentation is furnished, not filed, and not incorporated by reference into SEC filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.08,"calibrated_materiality_score":0.08,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422133,"accession_number":"0001683168-21-003829","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2021-08-23T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"PharmaCyte Biotech raises $70M in registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$70M from sale of 8.43M shares and 5.57M pre-funded warrants at $5.00 per share.","Unregistered Series A warrants for 7M shares at $5.00, exercisable immediately, 5-year term.","Net proceeds to address FDA clinical hold on IND for Phase 2b trial in pancreatic cancer and fund trial.","H.C. Wainwright acting as exclusive placement agent; closing expected on or about August 23, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422132,"accession_number":"0001683168-21-003431","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"PharmaCyte Biotech announces Nasdaq uplisting and pricing of $15M public offering at $4.25/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Common stock begins trading on Nasdaq Capital Market under PMCB on August 10, 2021.","Public offering of 3,529,412 units at $4.25 per unit (1 share + 1 warrant); gross proceeds ~$15M.","Warrants exercisable at $4.25, immediately, expire in 5 years; pre-funded warrants also offered.","H.C. Wainwright sole book-runner; underwriter granted 30-day option for up to 529,411 additional units.","Executive officers and directors subject to 90-day lock-up from prospectus supplement date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422131,"accession_number":"0001683168-21-003222","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2021-08-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"PharmaCyte Biotech reports preliminary FY2021 net loss of $3.6M, cash $2.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2021 was approx. $3.6M ($2.45 loss per share) vs. $3.8M ($4.23 loss per share) in FY2020.","Cash on hand as of April 30, 2021 was approx. $2.2M.","Results are preliminary and unaudited, subject to completion of financial closing procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422130,"accession_number":"0001683168-21-002921","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2021-07-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PharmaCyte Biotech effects 1-for-1,500 reverse stock split, reduces outstanding shares to ~1.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio 1:1,500; outstanding shares reduced from ~2.4B to ~1.6M.","Authorized shares decreased from 50B to 33,333,334; par value unchanged at $0.0001.","Effective July 12, 2021; temporary ticker PMCBD for 20 business days, then revert to PMCB.","CEO states split is a necessary step before Nasdaq listing and to support financing.","No fractional shares issued; proportionate voting power unaffected; rounding up to whole share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422129,"accession_number":"0001683168-21-002825","cik":1157075,"company_name":"PharmaCyte Biotech, Inc.","ticker":"PMCB","form_type":"8-K","filed_at":"2021-07-06T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"PharmaCyte shareholders approve 50B common share authorization increase and bylaw amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased to 50 billion shares ($0.0001 par); preferred stock to 10 million shares.","All seven director nominees elected; broker non-votes of ~701M shares.","2021 Equity Incentive Plan approved: 565.7M for, 116.4M against, 20.6M abstain.","Armanino LLP ratified as independent auditor for FY ending April 30, 2022.","Bylaw Amendment No. 4 adopted, adding cumulative voting rights for directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8747406.547894737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}